Particularly when: Failed closure, defined as requiring one or more attempts, exhibited a significant difference, with a higher risk in the IDRT group (26.7%) compared with BTM (6.7%, P = 0.003).
The other curiosity is the net profit per square centimetre conclusion: Biodegradable Temporizing Matrix incurred lower costs compared with IDRT but displayed a lower mean profit per square centimeter ($10.63 vs $22.53, P < 0.001).
Does this mean that the hospital's mark up on Integra is proportionally higher than for BTM such that while overall costs are higher for Integra use the net profit is higher?
Is there anyone out there who has experience in hospital finances who can explain this?
The Clinicians Speak, page-849
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.34 |
Change
-0.020(0.85%) |
Mkt cap ! $1.615B | |||
| Open | High | Low | Value | Volume |
| $2.34 | $2.37 | $2.32 | $2.004M | 857.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2441 | $2.33 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.34 | 19571 | 5 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.33 |
Change
-0.020 ( 1.24 %) |
||||
| Open | High | Low | Volume | ||
| $2.34 | $2.37 | $2.32 | 261156 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| PNV (ASX) Chart |